Eli Lilly shows positive phase 2 results for breast-cancer treatment Alimta

By Elaine Rigoli

Tampa, Fla., June 5 - Eli Lilly and Co. announced results of a phase 2 trial evaluating its leading thoracic cancer drug Alimta (pemetrexed) in first-line metastatic breast cancer. The study also detailed exploratory pharmacogenomic analyses to potentially identify the presence of specific biomarkers for Alimta.

The phase 2 study was a randomized, double-blind trial of 92 patients with locally advanced or metastatic breast cancer.

The two sets of patient groups were given two different doses of Alimta.

The study concluded that since efficacy and safety for both doses were similar, the lower dose (600 mg/m squared) is suitable for further study, according to a news release.

In addition, exploratory biomarker analysis suggests an efficacy correlation for FFGS (folypolyglutamate synthase) and TP (thymidine phosphorylase).

Lilly said it is considering plans for a phase 3 trial as well as further evaluation of the biomarkers that were explored.

Indianapolis-based Eli Lilly is a global developer of pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.